DOI:
10.1055/s-00000017
Experimental and Clinical Endocrinology & Diabetes
LinksClose Window
References
Lee J, Hong YS, Hong JY. et al.
Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant
colorectal cancer and predictive value of the RAS signature for treatment
response to cetuximab.
Invest New Drugs 2014;
32: 535-541
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.